E-6201 is under clinical development by Strategia Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how E-6201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

E-6201 overview

E-6201 is under development for the treatment of brain metastasis in BRAF V600-Mutated Metastatic Melanoma. It is administered topically and intravenously. E-6201 is a small molecule and synthetic analog of a fungal metabolite. The drug candidate acts by targets FLT3 (FMS-like tyrosine kinase 3), mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1) and mitogen activated protein kinase kinase kinase (MEKK1). It was also under development for plaque-type psoriasis, acute myeloid leukemia, myelodysplastic syndrome and chronic myelomonocytic leukemia.

For a complete picture of E-6201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.